Company:

Investors

MPM Capital www.mpmcapital.com Contact: Dr. Luke Evnin	New Enterprise Associates www.nea.com Contact: Dr. James Barrett
Hunt BioVentures www.huntbioventures.com Contact: Mr. Fulton Murray	Silicon Valley Capital Partners www.svbcapital.com Contact: Dr. Henry Chung
Boston Medical Investors Contact: Mr. Robert Carpenter	Ropes & Gray, LLP www.ropesgray.com Contact: Mr. Joel Freedman, Esq.

contact us

Change Text Size:

Recent News

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

7/30/2008 – Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the…

Peptimmune Announces the Second Close of Series D Private Financing

7/16/2008 – Peptimmune announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New…

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

6/17/2008 – Peptimmune announces first patient dosed in a phase Ib study of PI-2301 in multiple sclerosis patients in one of the most comprehensive studies of the…

View more articles in the News Archives